Results 1 - 1 of 1
Results 1 - 1 of 1. Search took: 0.02 seconds
[en] Therapeutic radiopharmaceuticals are a major role player in today’s nuclear medicine, especially for the treatment of cancer. One of the interesting and long practiced fields of their application is ‘radiation synovectomy,’ or in short ‘radiosynovectomy’. In the last decades, the production and quality control of radiopharmaceuticals for use in radiosynovectomy has gone from simple phosphorous-32 (32P) colloids to recently developed matrixes labelled with short/medium range beta emitters. It is a well-established technique with growing applications worldwide. However, the lack of generic and peer-reviewed production, quality control and clinical application guidelines and recommendations, are a major concern for their application in human patients. Based on both, IAEA’s global efforts in supporting Member States in the application of nuclear techniques in radiopharmacy and health, and on several requests from Member States as well as professional societies in recent years, formulation of an IAEA technical publication on the subject became pertinent. Currently, there is a lack of international standardized regulations of RSV production and clinical use. This publication is meant to be utilized by all involved professionals in the field by specifying ideal quality control and quality assurance procedures in the production of several radiopharmaceuticals for performing radiosynovectomy, as well as standard operation procedures needed for achieving successful therapeutic effects in patients.